Design Therapeutics Inc
DSGN
Company Profile
Business description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Contact
6005 Hidden Valley Road
Suite 110
CarlsbadCA92011
USAT: +1 858 293-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
55
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.30 | 16.50 | -0.18% |
| CAC 40 | 8,506.72 | 9.55 | 0.11% |
| DAX 40 | 24,983.30 | 8.67 | -0.03% |
| Dow JONES (US) | 48,804.06 | 821.91 | -1.66% |
| FTSE 100 | 10,676.90 | 7.84 | -0.07% |
| HKSE | 26,590.32 | 491.59 | -1.82% |
| NASDAQ | 22,627.27 | 258.79 | -1.13% |
| Nikkei 225 | 57,321.09 | 495.39 | 0.87% |
| NZX 50 Index | 13,532.31 | 111.88 | 0.83% |
| S&P 500 | 6,837.75 | 71.76 | -1.04% |
| S&P/ASX 200 | 9,022.30 | 12.10 | -0.13% |
| SSE Composite Index | 4,117.41 | 35.34 | 0.87% |